At day 90, TNF+CD4+ T cells (P = 0.0055) and IL-2+CD8+ T cells (P = 0.0271) were higher with GEMCOVAC-OM compared with GEMCOVAC-19. This evidence concerns the gene CD8A and ocular melanoma.